The reaffirmation of a Buy rating combined with a substantial increase in the price target from $25 to $60 by a reputable analyst firm like HC Wainwright & Co. is likely to be viewed positively by investors and could lead to a short-term increase in the stock price of Longboard Pharmaceuticals. The new price target suggests a significant upside potential from the current trading level, which may attract investor interest and buying pressure.